Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 15/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | PGK1 | P00558 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15254396 | 0.91 | FYN (0.52) | FYNPIM1CCNT1ABL1PGK1 | |
| SCHEMBL15255004 | 0.90 | FYN (0.51) | FYNPIM1CCNT1ABL1PGK1 | |
| SCHEMBL2946558 | 0.85 | MKNK1 (0.61) | FYNMKNK1 | |
| SCHEMBL15254301 | 0.85 | IRAK4 (0.45) | FYNMKNK1 | |
| SCHEMBL3453659 | 0.85 | IKBKB (0.47) | FYNPIM1CCNT1ABL1PGK1 | |
| SCHEMBL15254278 | 0.84 | FYN (0.47) | FYNMKNK1 | |
| SCHEMBL3453524 | 0.84 | MKNK1 (0.55) | FYNMKNK1 | |
| SCHEMBL3452716 | 0.84 | FYN (0.62) | FYNMKNK1 | |
| SCHEMBL15254917 | 0.83 | FYN (0.44) | FYNMKNK1 | |
| SCHEMBL15254573 | 0.82 | MKNK1 (0.48) | FYNMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-7820670-B2 | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOT2 | FYN 856/4885PIM1 2962/4885CCNT1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.